【摘要】 目的以影像学为标准,比较循环肿瘤DNA(ctDNA)与癌胚抗原(CEA)、糖链抗原19-9(CA 19-9)在局部晚期和晚期非小细胞肺癌(NSCLC)疗效评估中的敏感性。方法所有患者经过2次化疗或者靶向治疗后,分别于治疗前后检测CT以及肿瘤标志物CEA、CA 19-9,并收集外周血标本。采用荧光PCR法检测外周血总DNA量、完整DNA量及甲基化DNA拷贝数。影像学RESIST1.1标准作为疗效评估标准。结果以CT为参考标准,CEA评估治疗疗效的敏感性为54.17%,CA19-9评估治疗疗效的敏感性为64.58%,差异无统计学意义(P=0.299);ctDNA评估疗效的敏感性为47.92%,与CEA相比差异无统计学意义(P=0.540)。ctDNA与CA 19-9的敏感性相比无显著差异(P=0.100)。结论 CEA、CA 19-9、ctDNA对评估疗效的敏感性为CA 19-9最强,ctDNA最弱。更多还原

【Abstract】 Objective To compare the sensitivity of ctDNA,CEA and CA19-9 in the treatment of non-small cell lung cancer( NSCLC) according to imaging manifestation. Methods After two times of chemotherapy or targeted therapy,all patients were detected by CT,CEA and CA19-9 before and after treatment,and peripheral blood samples were collected. Fluorescence PCR was used to detectthe total DNA amount of peripheral blood,the total amount of DNA and the number of copies of methylated DNA. Imaging RESIST1. 1 standard was used as the standard for efficacy evaluation.Results Taking CT as the reference standard,the sensitivity of CEA in evaluating therapeutic efficacy was 54. 17%,and the sensitivity of CA 19-9 was 64. 58%,and there were no statistical differences( P = 0. 299). The sensitivity of ctDNA was 47. 92%,which showed no significant difference when compared with CEA( P = 0. 540). There was no significant difference in sensitivity between ctDNA and CA 19-9( P = 0. 100). Conclusion The sensitivity of CEA,CA19-9 and ctDNA in evaluating efficacy shows that CA 19-9 is the best and ctDNA is the worst.更多还原